In this video, Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses risk factors for progression in myeloproliferative neoplasms (MPNs), highlighting the important role that genetic aberrations and driver mutations play in disease. Dr Verstovsek first comments on mutations that play a role in disease progression, and then discusses other factors that influence patient outcome and the importance of early intervention. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.